Related Experiment Video
Updated: Apr 30, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Warfarin therapy--why one dose does not fit all!
Abstract:
We report an Indian adult female patient with Deep Vein Thrombosis (DVT), in whom it was difficult to achieve and maintain target INR on warfarin (oral anticoagulant) by conventional doses. Pharmacogenomics study for warfarin revealed that she had Homozygous mutant for CYP2C9 *3(CYP2C9 *3/*3) and Heterozygous mutant for VKORC 1(1639G >A) {genetic polymorphism double defect}. This conferred a greater sensitivity to her warfarin therapy in an otherwise conventional dose regime used in most patients, making her management challenging. This sensitivity (or resistance in other cases) can be assessed by this evidence based test and warfarin dosing could be individualised to avoid toxicity.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Dosage Regimen: Individualization
Therapeutic Drug Monitoring: Affecting Factors

